<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010396</url>
  </required_header>
  <id_info>
    <org_study_id>24.06.2019 V 1.0</org_study_id>
    <nct_id>NCT04010396</nct_id>
  </id_info>
  <brief_title>Immunological Responses in Bovine vs Mechanical Composite Grafts</brief_title>
  <acronym>IRBOcomp</acronym>
  <official_title>Clinical and Immunological Patterns of Non-infectious Aortic Graft Inflammation in Bovine vs Non-biological Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the first retrospective part of the study the investigators will conduct a data analysis
      of patients having received a bovine aortic graft. The investigators will analyze charts and
      CT / MRI at various time intervals and identify if there are signs of inflammation.

      In the second prospective part the investigators will select survivors from the first part
      with and without inflammation signs. If they consent to participate in the study the
      investigators will do a blood sampling in order to perform further immunological analysis.
      Additionally, the investigators will examine their quality of life by QoL SF-12
      questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 Retrospective database search on subjects that received a Shelhigh graft (n= 116) and
      subjects that received a mechanical graft (n=50) in a similar time frame, age, gender,
      co-morbidities, clinical history.

      Analyzing CT or MRI report at following time intervals: 3 - 6 months postoperatively, 1, 2
      and 3 years postoperatively (regular check-up appointments in clinics).

      Additionally, extraction of following data-set (based on availability): temperature, lab
      values (C-reactive protein, white blood count, Eosinophil count), pathology report and CT- /
      MRI- imaging in cases of re-operation.

      Firstly, identify if there is a graft inflammation (positive / negative group within the
      bovine group).

      Secondly, compare to mechanical group.

      Part 2 Choose 10 + 10 patients of the bovine group (with / without immune response) and 10 of
      the mechanical group in order to conduct further immunological testing and comparison. The
      immunological testing will include measurement of immunoglobulin E and immunoglobulin G
      antibodies against bovine protein, as well as in vitro T cell reactivity in Interleukin 4 and
      interferon-gamma Elispot. These parameters will characterize whether the patient mounted an
      adaptive immune response against the bovine protein. In addition, the investigators will
      measure total immunoglobulin G4 and Interleukin-6 levels in the serum of all patients, as
      additional inflammation markers.

      Contact patients to come into clinics for a visit, explain study. Blood sampling (1 serum and
      1 EDTA) after patients consent.

      Material will be sampled and sent in anonymized form via express courier to the Translational
      Immunology Lab at the University Hospital Basel. Samples will be processed within 24h to
      isolate peripheral blood mononuclear cells (PBMC) and serum. PBMC and Serum will be
      cryopreserved at -180°C and -80°C respectively. Samples will be analyzed in batches each
      including 3-5 subjects per group.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Response</measure>
    <time_frame>postoperatively, up to 30 years</time_frame>
    <description>Percentage of patients having received the bovine conduit graft showing a graft inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Response in Control Group</measure>
    <time_frame>postoperatively, up to 30 years</time_frame>
    <description>Comparison of the bovine group to patients having received a mechanical composite graft.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Defect</condition>
  <arm_group>
    <arm_group_label>Recipients of Bovine Graft</arm_group_label>
    <description>Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipients of Mechanical Graft</arm_group_label>
    <description>Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling: 1 EDTA and 1 Serum vial</description>
    <arm_group_label>Recipients of Bovine Graft</arm_group_label>
    <arm_group_label>Recipients of Mechanical Graft</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples (1 EDTA + 1 Serum vial)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Part 1: n=116 bovine (total amount of recipients of the Shelhigh graft at the
        investigators' institution).

        50 (mechanical control)

        Part 2: n= 10 (bovine with immune response) +10 (bovine without immune response) +10
        (mechanical control)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of the bovine graft or mechanical graft. For the prospective part 2: able
             to give informed consent by signature, age, matching characteristics and time frame.

        Exclusion Criteria:

          -  Individuals of the patient cohort from the last 20 years who indicated that their data
             cannot be utilized for future research will be excluded from the study.

          -  Inability or any contraindications to undergo the planned investigated intervention,
             clinically significant concomitant diseases precluding ambulatory control in the day
             clinic in Bern.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ThierryThierry Prof. Dr. med. Carrel</last_name>
    <role>Study Chair</role>
    <affiliation>Departmnet Chair</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Carrel TP, Schoenhoff FS, Schmidli J, Stalder M, Eckstein FS, Englberger L. Deleterious outcome of No-React-treated stentless valved conduits after aortic root replacement: why were warnings ignored? J Thorac Cardiovasc Surg. 2008 Jul;136(1):52-7. doi: 10.1016/j.jtcvs.2007.09.047. Epub 2008 May 27.</citation>
    <PMID>18603053</PMID>
  </reference>
  <reference>
    <citation>Carrel T, Reineke D, Englberger L. Another report on unfavourable long-term outcome following implantation of the Shelhigh No-React™ valved tube graft. Eur J Cardiothorac Surg. 2016 Dec;50(6):1179-1180. doi: 10.1093/ejcts/ezw205. Epub 2016 Jun 14.</citation>
    <PMID>27307482</PMID>
  </reference>
  <reference>
    <citation>Reineke DC, Kaya A, Heinisch PP, Oezdemir B, Winkler B, Huber C, Heijmen RH, Morshuis W, Carrel TP, Englberger L. Long-term follow-up after implantation of the Shelhigh® No-React® complete biological aortic valved conduit. Eur J Cardiothorac Surg. 2016 Jul;50(1):98-104. doi: 10.1093/ejcts/ezv452. Epub 2015 Dec 30.</citation>
    <PMID>26719402</PMID>
  </reference>
  <reference>
    <citation>Gisler F, Huber C, Wenaweser P, Carrel T. Severe calcification of a Shelhigh stentless valved conduit. Eur J Cardiothorac Surg. 2014 Aug;46(2):334. doi: 10.1093/ejcts/ezt569. Epub 2013 Dec 11.</citation>
    <PMID>24335263</PMID>
  </reference>
  <reference>
    <citation>Schoenhoff FS, Loup O, Gahl B, Banz Y, Pavlovic M, Pfammatter JP, Carrel TP, Kadner A. The Contegra bovine jugular vein graft versus the Shelhigh pulmonic porcine graft for reconstruction of the right ventricular outflow tract: a comparative study. J Thorac Cardiovasc Surg. 2011 Mar;141(3):654-61. doi: 10.1016/j.jtcvs.2010.06.068. Epub 2011 Jan 20.</citation>
    <PMID>21255796</PMID>
  </reference>
  <reference>
    <citation>Carrel TP. Another disastrous outcome following aortic root replacement with the Shelhigh No-react aortic valved tube. Thorac Cardiovasc Surg. 2008 Aug;56(5):314-5. doi: 10.1055/s-2008-1038472.</citation>
    <PMID>18615385</PMID>
  </reference>
  <reference>
    <citation>Englberger L, Noti J, Immer FF, Stalder M, Eckstein FS, Carrel TP. The Shelhigh No-React bovine internal mammary artery: a questionable alternative conduit in coronary bypass surgery? Eur J Cardiothorac Surg. 2008 Feb;33(2):222-4. Epub 2007 Dec 20.</citation>
    <PMID>18083039</PMID>
  </reference>
  <reference>
    <citation>Sahin A, Müggler O, Sromicki J, Caliskan E, Reser D, Emmert MY, Alkadhi H, Maisano F, Falk V, Holubec T. Long-term follow-up after aortic root replacement with the Shelhigh® biological valved conduit: a word of caution! Eur J Cardiothorac Surg. 2016 Dec;50(6):1172-1178. doi: 10.1093/ejcts/ezw167. Epub 2016 May 26.</citation>
    <PMID>27229673</PMID>
  </reference>
  <reference>
    <citation>Kaya A, Heijmen RH, Kelder JC, Schepens MA, Morshuis WJ. Stentless biological valved conduit for aortic root replacement: initial experience with the Shelhigh BioConduit model NR-2000C. J Thorac Cardiovasc Surg. 2011 May;141(5):1157-62. doi: 10.1016/j.jtcvs.2010.07.009. Epub 2010 Sep 15.</citation>
    <PMID>20832085</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

